Share Name Share Symbol Market Type Share ISIN Share Description
Destiny Pharma Plc LSE:DEST London Ordinary Share GB00BDHSP575 ORD GBP0.01
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 35.50 35.00 36.00 35.50 35.50 35.50 3,582 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -6.0 -11.9 - 16

Destiny Pharma Share Discussion Threads

Showing 51 to 74 of 75 messages
Chat Pages: 3  2  1
DateSubjectAuthorDiscuss
20/1/2020
07:30
20 January 2020 Destiny Pharma plc ("Destiny Pharma" or "the Company") Positive update on the development of new XF--platform drug formulations Collaboration with MedPharm Ltd. delivers data profiling new XF--platform drug formulations as potential treatments for dermal and ocular infections New formulations support a growing pipeline alongside lead drug asset, XF-73, currently in Phase 2b development with data anticipated in mid-2020 Brighton, United Kingdom - 20 January 2020 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development of novel, hospital infection prevention treatments that address the global challenge of antimicrobial resistance (AMR), announces the completion of the initial phase of its project with MedPharm to develop new topical formulations of the Company's novel XF--platform drugs. Further to forming the collaboration with MedPharm, as announced on 27 March 2019, the project has identified a range of new, stable XF formulations with promising drug release profiles and scope for delivery of XF drugs (including clinical stage XF-73, XF-70 and DPD-207 compounds) designed to treat dermal and ocular infections. These formulations will form the basis of XF drug delivery for Destiny Pharma's pre-clinical and clinical programmes and treatments for both acute and chronic infections. Selected formulations will also be incorporated into ongoing grant funded projects including the Company's UK-China AMR, Innovate UK grant funded collaboration, as announced on 25 January 2019. Neil Clark, CEO of Destiny Pharma, commented: "We are pleased to announce positive progress made during 2019 to develop new formulations of XF drugs from our novel antimicrobial XF--platform. There is an unmet medical need for novel anti-infectives that address dermal and ocular infections with a significantly reduced potential for generating antimicrobial resistance. We look forward to continuing to work with MedPharm to support the expansion of our pipeline as we take select formulations into our ongoing pre--clinical and clinical studies. Our lead drug candidate from the XF-platform, XF--73 nasal gel, for the prevention of post--surgical infections, is currently in Phase 2b development with data expected in mid-2020." Eugene Ciolfi, CEO of MedPharm, commented: "MedPharm's rigorous development methodology and novel in vitro performance testing capabilities have supported the success of this project. We are delighted to be able to continue our collaboration with Destiny Pharma to advance and broaden its product pipeline and address this unmet medical need." MedPharm is a world leading contract provider of topical and transdermal product design and formulation development services using sophisticated in vitro models to de--risk development programmes.
bamboo2
31/12/2019
10:51
Taken a small amount. Link to current trial Https://clinicaltrials.gov/ct2/show/NCT03915470
bamboo2
30/12/2019
12:05
Have been invested here since pre-IPO - I'm well down but trying to decide whether to top up/average down. The story is great, so this is a classic binary Biostock. If 2b trials pass it will multibag, if 2b fails it will bomb. For me the risk is mitigated by the fact that MCAP is only 19m, whilst net assets of 12m (mainly cash). Current cash burn is about 4m pa so plenty of working capital to continue operations for a few years. However, I think I read somewhere that phase III trials would cost around 30m, so there would have to be a major placing to fund this. My understanding is that in the industry that if 2b trials are successful, the success rate of ph 3 is very high (can anyone confirm this?); therefore, should be able to attract IIs if 2b is passed.
kipper1960
30/12/2019
09:01
Chart shows a potential turn today. Eod close above 43 confirms a tp at 50 Longer term tp 58
bamboo2
18/12/2019
08:32
#DEST new guidelines are easing the way for Destiny's XF-73 product in Asia Pacific. Remember, this is all about the prevention of post surgical infection, not the treatment https://equitydevelopment.co.uk/edreader/?d=%3D%3DQM3YjM
edmonda
16/12/2019
18:29
Very odd. I've been stock building this share for many weeks as I really like the potential, having bought these about 10 years ago initially as an EIS investment. However, every purchase I make keeps showing as a sale (in red) in the daily Trades listing. Any ideas why this might be the case?
supracat
25/9/2019
15:23
The interesting point in the video above is that he estimated the phase III will cost about £30m to complete. The large companies are not interested in the antibiotics space and Destiny will struggle fund that sort of amount and if they do there will be massive dilution. And if it is approved will there be any uptake if a very cheap generic does the job just as well? Low margin, low sales and lots of time/funding still to go. I do hold a few but I still need to be convinced.
pdt
16/9/2019
08:58
As mentioned before. Biased and own more than i should but after watching that video, it has confirmed the reason i invested.Never like CEO interviews as i always find them believable and passionate about their companies future, but to me, this feels ok.Good luck to all that have stuck with it.Cheers
aspringo
16/9/2019
08:13
hTTps://youtu.be/JP7OHAWH3A4
cheshire man
10/9/2019
10:26
I'm biased as own too many, but i just have a feeling that this will end out ok.In the right space at the right time with tech that seems to work.Certainly no share buying advice intended.Fingers crossed for all holders.
aspringo
10/9/2019
10:09
That news bringing in a few buyers and up over 5% I see
cheshire man
20/8/2019
10:14
Garraway/CF stock went to WINS, they’ve been moving the stock on since then, I’d guess when they’re finished this will recover, no offer available from any of the other mm’s.
bumpa33
15/8/2019
13:22
`The holding on B'berg was held under the name "City Financial". When CF went pop, Garraway took on the fund. The fund was a UK Absolute Return by name but absolute disaster in terms of terrible fund performance and high volatility, so was wound up pdq. So the good news for DEST shareholders is that the recent kicking the stock has just had was/is a) technical and b) over and done with. Up to the company now to prove its worth.
johnniew156
15/8/2019
11:30
There's my answer. RNS.
cottoner
15/8/2019
06:41
A query wrt Garraway's holding. DEST have just under 44m shares in issue. 3% is just over 1.3m shares. I can't see any evidence of Garraway being/having been a major shareholder. Am I missing something?
cottoner
14/8/2019
12:36
Yes agreed johnniew. A further 125k sold this morning so possibly the last of the Garraway stake. No doubt there'll be an RNS to confirm v. soon.
gaiusgracchus
14/8/2019
10:24
Literally a couple of minutes after my posting, B'berg popped up with a delayed trade on the QR page. 1.4m shares were crossed at 35p at 15:56.18 yesterday, so yesterday's volume has been adjusted to 1,438,389 shares. In my view it would be extremely coinciental if this sale (of 1.4m shares) was not the balance of the 1.521943m Garraway stake that I am guessing was placed directly into market at least initially & ended up smashing the share price yesterday.
johnniew156
14/8/2019
10:01
Nice spot, makes sense. Thanks. Providing no upsets from the company themselves, it may be an opportunity, or then again?Good luck with any aim purchase.
aspringo
14/8/2019
09:59
Shareholders should be aware that the Garraway Capital former City of London Fund UK Absolute equity fund managed by David Crawford is being wound up. The fund held 1,521,943 shares of DEST according to Bloomberg as at 30.06.19. Could be coincidence, but a badly managed large sell order would explain the volume surge. hxxps://citywire.co.uk/funds-insider/news/troubled-absolute-return-fund-to-close-four-months-after-suspension/a1254614
johnniew156
14/8/2019
08:52
I'm going for a placing
mikeh30
14/8/2019
07:31
Just my tuppence worth on this share.I'm foolishly topping up and 3 of the purchase made today are mine tjough showing as sales.As far as i can see the story hasnt changed. So far delivered exactly as promised but now the share price is at a fraction of the IPO.Someone may know whats going on, but until then I'll take a chance and keep accumalating.Apologies for my naivety. Good luck all
aspringo
27/5/2019
21:11
Interesting what you say about the length of time this company has taken to get to where it is. I bought some of these after IPO. Not at the top thank goodness but still, I'm down a fair bit. I've subsequently decided to stop investing in biotech stocks. Just don't have the insight required. This doesn't add much to the discussion on Destiny (I'm still holding) but I wish I knew how to figure out if the drug is likely to be successful - in which case we should be piling in - or if it's going to be a dud. I don't know...clearly.
gaiusgracchus
16/4/2019
09:23
First bought into this pre IPO over 10 years ago. Its been a long time developing this so called super drug. Would see it 20 bag and a lot more if it did, but after all this time, I have strong doubts.
jack jebb
16/4/2019
09:15
updated Equity Development research following FY18 results reiterates attractions of their novel antimicrobials pipeline and raises fair value level . Note freely available here: https://www.equitydevelopment.co.uk/edreader/?ltkn=%5bID%5d&d=%3D%3DQO2UjM
edmonda
Chat Pages: 3  2  1
Your Recent History
LSE
DEST
Destiny Ph..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200228 19:46:22